Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

GSK to present data from across its respiratory portfolio at 2025 ATS International Congress in San Francisco: London, UK Monday, May 5, 2025, 10:00 Hrs [IST] GSK plc announced da ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. GSK has three segments: Specialty Medicines (HIV, Oncology, Immunology/Respiratory and Other), Vaccines ...

GSK plc (NYSE:GSK) Q1 2025 Earnings Call Transcript ... we continue to expect FDA approvals for Nucala COPD imminently, Blenrep in July, and depemokimab by the end of the year.

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it posted a 4% rise in Q1 2025 sales to £7.52bn ($10.05bn), driven by growth ...

GSK (LSE:GSK) reported a significant improvement in its first-quarter earnings, with sales, net income, and earnings per share all showing promising growth. This announcement coincided with a 5.14% ...